Antibiotic prophylaxis in cystic fibrosis: inhaled cephaloridine as an adjunct to oral cloxacillin
- PMID: 6981695
- DOI: 10.1016/s0022-3476(82)80726-9
Antibiotic prophylaxis in cystic fibrosis: inhaled cephaloridine as an adjunct to oral cloxacillin
Abstract
The effect of prophylactic antibiotics on bacterial colonization of the respiratory tract and on general progression of cystic fibrosis was studied in a two-year prospective study of 47 mildly to moderately affected patients. One group of patients received inhaled cephaloridine and the other received no inhaled antibiotic; both groups received cloxacillin orally. Carriage of Haemophilus influenzae was greater in the group not receiving inhaled antibiotic (55% vs 20%). Rates of carriage of Staphylococcus aureus (23%). Pseudomonas aeruginosa (greater than 90%). Pseudomonas cepacia (45%), and other organisms were similar in both groups. There were no significant differences between the two groups in incidence of respiratory tract infections or hospital admissions, clinical scores, radiologic scores, or rate of change of pulmonary function. Although continuous antistaphylococcal antibiotic prophylaxis may be successful in suppressing colonization with S. aureus, it may also contribute to the high rates of carriage of Ps. aeruginosa and Ps. cepacia observed in patients with cystic fibrosis.
Similar articles
-
Induced sputum compared to bronchoalveolar lavage in young, non-expectorating cystic fibrosis children.J Cyst Fibros. 2014 Jan;13(1):106-10. doi: 10.1016/j.jcf.2013.05.013. Epub 2013 Jun 24. J Cyst Fibros. 2014. PMID: 23806622 Clinical Trial.
-
[Isolation frequency of Burkholderia cepacia from cystic fibrosis patients].Mikrobiyol Bul. 2002 Jan;36(1):1-10. Mikrobiyol Bul. 2002. PMID: 12476760 Turkish.
-
Qualitative and quantitative microbiological analysis of sputa of 102 patients with cystic fibrosis.Infection. 1987 Jul-Aug;15(4):270-7. doi: 10.1007/BF01644137. Infection. 1987. PMID: 3117700
-
Prophylactic antibiotics in cystic fibrosis: a conviction without evidence?Pediatr Pulmonol. 2005 Dec;40(6):471-6. doi: 10.1002/ppul.20305. Pediatr Pulmonol. 2005. PMID: 16200640 Review.
-
[Pathogenesis and diagnosis of bacterial airway infections in patients with cystic fibrosis].Ned Tijdschr Geneeskd. 1995 Nov 18;139(46):2346-9. Ned Tijdschr Geneeskd. 1995. PMID: 7501072 Review. Dutch. No abstract available.
Cited by
-
Prophylactic anti-staphylococcal antibiotics for cystic fibrosis.Cochrane Database Syst Rev. 2020 Sep 30;9(9):CD001912. doi: 10.1002/14651858.CD001912.pub5. Cochrane Database Syst Rev. 2020. PMID: 32997797 Free PMC article.
-
Biology of Pseudomonas aeruginosa in relation to pulmonary infection in cystic fibrosis.J R Soc Med. 1986;79 Suppl 12(Suppl 12):13-8. J R Soc Med. 1986. PMID: 2425090 Free PMC article. Review. No abstract available.
-
Localization of the peptide transporter PEPT2 in the lung: implications for pulmonary oligopeptide uptake.Am J Pathol. 2001 Feb;158(2):707-14. doi: 10.1016/S0002-9440(10)64013-8. Am J Pathol. 2001. PMID: 11159208 Free PMC article.
-
Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis.Cochrane Database Syst Rev. 2018 Mar 30;3(3):CD001021. doi: 10.1002/14651858.CD001021.pub3. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2022 Nov 14;11:CD001021. doi: 10.1002/14651858.CD001021.pub4. PMID: 29607494 Free PMC article. Updated. Review.
-
Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis.Cochrane Database Syst Rev. 2022 Dec 13;12(12):CD009650. doi: 10.1002/14651858.CD009650.pub5. Cochrane Database Syst Rev. 2022. PMID: 36511181 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical